Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Stock Price Up 0.9% - Here's Why

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR saw a stock price increase of 0.9%, closing at $8.49 on Friday, with trading volume up by 13% compared to the average.
• The company reported $0.16 earnings per share (EPS) for its last quarterly results, exceeding the consensus estimate of $0.14, despite falling short of revenue expectations with $672.90 million versus an estimated $719.55 million.
• Shionogi specializes in the research and development of various pharmaceutical products, including treatments for HIV, COVID-19, and influenza.

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) shot up 0.9% during trading on Friday . The company traded as high as $8.51 and last traded at $8.49. 59,778 shares changed hands during mid-day trading, an increase of 13% from the average session volume of 52,947 shares. The stock had previously closed at $8.41.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a fifty day moving average price of $8.79 and a 200 day moving average price of $8.40. The company has a current ratio of 6.63, a quick ratio of 6.13 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its quarterly earnings results on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.02. The company had revenue of $672.90 million during the quarter, compared to the consensus estimate of $719.55 million. Equities research analysts anticipate that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.